ProCE Banner Activity

V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation

Slideset Download
Conference Coverage

The combination of CPX-351 and midostaurin showed manageable toxicity and suggested promising efficacy in patients with newly diagnosed AML and either a FLT3 ITD or TKD mutation.

Released: December 17, 2022

Expiration: December 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen